ASEM 문헌 요약
Official American Association of Clinical Endocrinology document (2022) on “2022 Consensus Statement on Immune Checkpoint Inhibitor-Mediated Endocrinopathies”. This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews.
이 요약은 문서를 식별하는 데 도움이 됩니다. 임상 권고사항은 항상 공식 버전과 업데이트 날짜를 확인하십시오.
공식 문서